CClinicalTrials.gg
CompletedNCT03278249Updated Sep 19, 2024Results posted

Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma

An interventional study of Modified Atkins Ketogenic Diet in Glioblastoma, sponsored by University of Cincinnati. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University of Cincinnati · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to see if people can produce ketones in their blood with the modified Atkins diet. Modified Atkins diet is a diet that produces ketones in your blood by restricting carbohydrates to \<20 grams per day. Ketones are substances that are produced in the blood when fat is being broken down. Ketones may help radiation work better and may starve your tumor because it is thought that some brain tumors can not use ketones to grow and can only use sugar or glucose to grow.

02

Conditions studied

  • Glioblastoma

Keywords

  • brain tumor
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically confirmed primary malignant glioma, Grade III or IV
  • No uncontrolled infection or other active malignancy or chronic systemic immune therapy.
  • ECOG performance status \< 3.
  • Life expectancy > three months.
  • Adequate labs

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of genetic disorder of fat metabolism.
  • Type 2 diabetes diagnosed with a hemoglobin A1C > 6.4
  • Allergic to dairy or lactose intolerance
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Modified Atkins Ketogenic Diet

    Modified Atkins Ketogenic Diet in combination with Temodar and Radiation

    Other: Modified Atkins Ketogenic Diet

Interventions

  • OtherModified Atkins Ketogenic Diet

    Less than 20 grams of carbohydrates per day

05

What researchers measure

Primary outcomes

  1. Number of Participants With Ketosis

    Ketosis measured by serum beta-hydroxybuterate. Ketosis is defined as having serum beta-hydroxybuterate (BHB) at \> 0.05 mM. Participants' BHB levels were assessed at 6 weeks after starting the study. The number of participants who had BHB at \> 0.05 mM were considered to have entered into ketosis. 9 of 9 participants met this criteria.

    Time frame: 6 weeks

Secondary outcomes

  1. Number of Participants With Progression Free Survival

    Progression Free Survival (PFS) is defined as the percentage of patients without progression at 6 months. Progression will be evaluated via Radiographic Assessment in Neuro-oncology (RANO) criteria: \>5 mm increase in maximal diameter, as well as ≥ 25% increase in the sum of the products of the progressing.

    Time frame: 6 months

  2. Assessment of Survival

    Time frame: 2 years

06

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneModified Atkins Ketogenic Diet
Started12
Completed9
Not completed3
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Ketosis

Ketosis measured by serum beta-hydroxybuterate. Ketosis is defined as having serum beta-hydroxybuterate (BHB) at \> 0.05 mM. Participants' BHB levels were assessed at 6 weeks after starting the study. The number of participants who had BHB at \> 0.05 mM were considered to have entered into ketosis. 9 of 9 participants met this criteria.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Ketosis
ParticipantsModified Atkins Ketogenic Diet
Number of Participants With Ketosis9
SecondaryNumber of Participants With Progression Free Survival

Progression Free Survival (PFS) is defined as the percentage of patients without progression at 6 months. Progression will be evaluated via Radiographic Assessment in Neuro-oncology (RANO) criteria: \>5 mm increase in maximal diameter, as well as ≥ 25% increase in the sum of the products of the progressing.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Progression Free Survival
ParticipantsModified Atkins Ketogenic Diet
Number of Participants With Progression Free Survival6
SecondaryAssessment of Survival
Time frame:
2 years
Reported as:
Count of participants · Participants
Assessment of Survival
ParticipantsModified Atkins Ketogenic Diet
Assessment of Survival6

Adverse events

Collected over Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Modified Atkins Ketogenic Diet3/9 (33.3%)6/9 (66.7%)9/9 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventModified Atkins Ketogenic Diet
Febrile neutropeniaBlood and lymphatic system disorders2/9
Memory impairmentNervous system disorders1/9
Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-lowerMusculoskeletal and connective tissue disorders1/9
HydrocephalusNervous system disorders1/9
Infection with unknown ANC - WoundInfections and infestations1/9
Investigations, please specifyInvestigations1/9
Leukocytes (total WBC)Investigations1/9
Lymphatics - Other (Specify, __)Blood and lymphatic system disorders1/9
Neutrophils/granulocytes (ANC/AGC)Investigations1/9
PlateletsInvestigations1/9
Most frequent other events
Showing 10 of 57
Most frequent other events
EventModified Atkins Ketogenic Diet
FatigueGeneral disorders7/9
ConstipationGastrointestinal disorders6/9
Rash: dermatitis associated with radiation - ChemoradiationSkin and subcutaneous tissue disorders4/9
DiarrheaGastrointestinal disorders3/9
DizzinessNervous system disorders3/9
NauseaGastrointestinal disorders3/9
AnxietyPsychiatric disorders2/9
BruisingInjury, poisoning and procedural complications2/9
Edema: limbGeneral disorders2/9
Hair loss/alopecia (scalp or body)Skin and subcutaneous tissue disorders2/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Modified Atkins Ketogenic Diet
<=18 years0
Between 18 and 65 years7
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)Modified Atkins Ketogenic Diet
Female6
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Modified Atkins Ketogenic Diet
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Modified Atkins Ketogenic Diet
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Modified Atkins Ketogenic Diet
United States9
07

Study locations

1 site
  • UC Health
    Cincinnati, Ohio 45219, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 18, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03278249
Lead sponsor
University of Cincinnati
Responsible party
Rekha Chaudhary (Associate Professor of Medicine, University of Cincinnati) — Principal investigator
First posted
Sep 11, 2017
Start date
Oct 12, 2017
Primary completion
Dec 1, 2021
Completion
Jan 1, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Rekha Chaudhary, MD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion